Drugs / EP-104IAR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04120402 | Sep 2021 → May 2023 | osteoarthritis, knee | Eupraxia Pharmaceuticals Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP-104IAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04120402 ↗ |
| Route | Other | “EP-104IAR, a long-acting formulation of fluticasone propionate for intra-articular injection” PMID 39401503 ↗ Oct 2024 |